Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 03-May-24 7:21 PM View:  | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 03-May-24 | Sale (Planned) | 36,248 | $1.96 | $71,031.60 | (1%) 2.66M to 2.62M | |
| 03-May-24 7:21 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 01-May-24 | Payment of Exercise | 73,824 | $1.93 | $142,576.00 | (3%) 2.73M to 2.66M | |
| 03-May-24 7:23 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 01-May-24 | Payment of Exercise | 88,544 | $1.93 | $171,005.00 | (< 1%) 15.03M to 14.94M | |
| 03-May-24 7:19 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 01-May-24 | Payment of Exercise | 88,544 | $1.93 | $171,005.00 | (< 1%) 15.94M to 15.85M | |
| 05-Feb-24 6:11 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 05-Feb-24 | Sale (Planned) | 36,248 | $2.22 | $80,503.20 | (1%) 2.77M to 2.73M | |
| 05-Feb-24 6:10 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 01-Feb-24 | Gift | 116,592 | -- | -- | 4% 2.9M to 3.02M | |
| 05-Feb-24 6:09 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 01-Feb-24 | Payment of Exercise | 480,664 | $2.29 | $1,102,550.00 | (3%) 15.51M to 15.03M | |
| 05-Feb-24 6:11 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 01-Feb-24 | Payment of Exercise | 72,768 | $2.29 | $166,915.00 | (3%) 2.84M to 2.77M | |
| 05-Feb-24 6:10 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 01-Feb-24 | Gift | 116,592 | -- | -- | (4%) 2.92M to 2.8M | |
| 05-Feb-24 6:11 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 01-Feb-24 | Payment of Exercise | 480,200 | $2.29 | $1,101,480.00 | (3%) 16.42M to 15.94M | |
| 05-Feb-24 6:10 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 01-Feb-24 | Payment of Exercise | 103,408 | $2.29 | $237,197.00 | (3%) 3.02M to 2.92M | |
| 22-Nov-23 5:09 PM View: | Edwards Martin Director | Verona Pharma Plc (VRNA) | 20-Nov-23 | Private Purchase | 33,736 | $1.84 | $61,973.00 | 30% 111.06K to 144.8K | |
| 08-Nov-23 4:15 PM View: | Ebsworth David R Director | Verona Pharma Plc (VRNA) | 06-Nov-23 | Private Purchase | 160,000 | $1.98 | $316,080.00 | 23% 684.64K to 844.64K | |
| 03-Nov-23 8:11 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 03-Nov-23 | Sale (Planned) | 58,752 | $1.92 | $112,804.00 | (2%) 2.9M to 2.84M | |
| 03-Nov-23 8:11 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 01-Nov-23 | Payment of Exercise | 173,136 | $1.74 | $301,915.00 | (6%) 3.07M to 2.9M | |
| 03-Nov-23 8:08 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 01-Nov-23 | Payment of Exercise | 809,008 | $1.74 | $1,410,750.00 | (5%) 16.32M to 15.51M | |
| 03-Nov-23 8:09 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 01-Nov-23 | Payment of Exercise | 173,904 | $1.74 | $303,254.00 | (6%) 3.08M to 2.9M | |
| 03-Nov-23 8:09 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 01-Nov-23 | Gift | 196,096 | -- | -- | 7% 2.88M to 3.08M | |
| 03-Nov-23 8:09 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 01-Nov-23 | Payment of Exercise | 809,008 | $1.74 | $1,410,750.00 | (5%) 17.23M to 16.42M | |
| 03-Nov-23 8:09 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 01-Nov-23 | Gift | 196,096 | -- | -- | (7%) 2.9M to 2.71M | |
| 24-Oct-23 4:06 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 20-Oct-23 | Grant | 200,000 | -- | -- | 7% 2.68M to 2.88M | |
| 24-Oct-23 4:06 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 20-Oct-23 | Grant | 800,000 | -- | -- | 5% 16.43M to 17.23M | |
| 24-Oct-23 4:06 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 20-Oct-23 | Grant | 200,000 | -- | -- | 7% 2.87M to 3.07M | |
| 24-Oct-23 4:05 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 20-Oct-23 | Grant | 800,000 | -- | -- | 5% 15.52M to 16.32M | |
| 07-Aug-23 9:15 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 07-Aug-23 | Gift | 89,976 | -- | -- | (3%) 2.77M to 2.68M | |
| 07-Aug-23 9:17 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 07-Aug-23 | Sale (Planned) | 8,616 | $2.47 | $21,263.40 | (< 1%) 16.44M to 16.43M | |
| 07-Aug-23 9:15 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 07-Aug-23 | Sale (Planned) | 1,512 | $2.47 | $3,731.46 | (< 1%) 2.68M to 2.68M | |
| 07-Aug-23 9:15 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 07-Aug-23 | Gift | 89,976 | -- | -- | 3% 2.68M to 2.77M | |
| 07-Aug-23 9:19 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 07-Aug-23 | Sale (Planned) | 1,600 | $2.47 | $3,948.64 | (< 1%) 2.87M to 2.87M | |
| 07-Aug-23 9:17 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 07-Aug-23 | Sale (Planned) | 8,616 | $2.47 | $21,263.40 | (< 1%) 15.53M to 15.52M | |
| 07-Aug-23 9:15 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 04-Aug-23 | Sale (Planned) | 26,352 | $2.50 | $65,858.90 | (< 1%) 2.71M to 2.68M | |
| 07-Aug-23 9:19 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 04-Aug-23 | Sale (Planned) | 27,944 | $2.50 | $69,837.60 | (< 1%) 2.9M to 2.87M | |
| 07-Aug-23 9:17 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 04-Aug-23 | Sale (Planned) | 150,000 | $2.50 | $374,880.00 | (< 1%) 15.68M to 15.53M | |
| 07-Aug-23 9:17 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 04-Aug-23 | Sale (Planned) | 150,000 | $2.50 | $374,880.00 | (< 1%) 16.59M to 16.44M | |
| 07-Aug-23 9:19 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 03-Aug-23 | Sale (Planned) | 50,600 | $2.55 | $128,790.00 | (2%) 2.95M to 2.9M | |
| 07-Aug-23 9:17 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 03-Aug-23 | Sale (Planned) | 117,272 | $2.54 | $297,754.00 | (< 1%) 15.8M to 15.68M | |
| 07-Aug-23 9:17 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 03-Aug-23 | Sale (Planned) | 117,272 | $2.54 | $297,754.00 | (< 1%) 16.71M to 16.59M | |
| 07-Aug-23 9:15 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 03-Aug-23 | Sale (Planned) | 20,608 | $2.54 | $52,323.70 | (< 1%) 2.73M to 2.71M | |
| 03-Aug-23 8:29 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 02-Aug-23 | Sale (Planned) | 73,704 | $2.59 | $191,114.00 | (< 1%) 16.78M to 16.71M | |
| 03-Aug-23 8:30 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 02-Aug-23 | Sale (Planned) | 12,944 | $2.59 | $33,563.80 | (< 1%) 2.74M to 2.73M | |
| 03-Aug-23 8:27 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 02-Aug-23 | Sale (Planned) | 13,728 | $2.59 | $35,596.70 | (< 1%) 2.97M to 2.95M | |
| 03-Aug-23 8:31 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 02-Aug-23 | Sale (Planned) | 73,704 | $2.59 | $191,114.00 | (< 1%) 15.87M to 15.8M | |
| 03-Aug-23 8:30 PM View: | Poll Claire General Counsel | Verona Pharma Plc (VRNA) | 01-Aug-23 | Sale (Planned) | 18,608 | $2.68 | $49,850.80 | (< 1%) 2.76M to 2.74M | |
| 03-Aug-23 8:27 PM View: | Rickard Kathleen A. Chief Medical Officer | Verona Pharma Plc (VRNA) | 01-Aug-23 | Sale (Planned) | 19,736 | $2.68 | $52,872.70 | (< 1%) 2.99M to 2.97M | |
| 03-Aug-23 8:31 PM View: | Hahn Mark W Chief Financial Officer | Verona Pharma Plc (VRNA) | 01-Aug-23 | Sale (Planned) | 105,944 | $2.68 | $283,824.00 | (< 1%) 15.98M to 15.87M | |
| 03-Aug-23 8:29 PM View: | Zaccardelli David President and CEO Director | Verona Pharma Plc (VRNA) | 01-Aug-23 | Sale (Planned) | 105,944 | $2.68 | $283,824.00 | (< 1%) 16.89M to 16.78M | |
| 15-May-23 6:06 PM View: | Gupta Rishi Director | Verona Pharma Plc (VRNA) | 15-May-23 | Sale | 359,713 | $20.08 | $7,222,480.00 | (9%) 4.14M to 3.78M | |
| 15-May-23 6:07 PM View: | Orbimed Advisors LLC Director | Verona Pharma Plc (VRNA) | 15-May-23 | Sale Duplicate | 359,713 | $20.08 | $7,222,480.00 | (9%) 4.14M to 3.78M | |
| 15-May-23 6:06 PM View: | Gupta Rishi Director | Verona Pharma Plc (VRNA) | 12-May-23 | Sale | 43,200 | $21.64 | $934,848.00 | (1%) 4.18M to 4.14M | |
| 15-May-23 6:07 PM View: | Orbimed Advisors LLC Director | Verona Pharma Plc (VRNA) | 12-May-23 | Sale Duplicate | 43,200 | $21.64 | $934,848.00 | (1%) 4.18M to 4.14M |
